SPC363
Mengishnettlu (Neisseria meningitidis) fjölsykra úr hópi A, mengishnettlufjölsykra úr hópi C, mengishnettlufjölsykra úr hópi W-135, mengishnettlufjölsykra úr hópi Y, hver um sig tengd við stjarfaeitursburðarefnisprótín
Status:
VeittApplication date:
8.12.2021Application published:
15.1.2022Grant published:
15.2.2024
Max expiry date:
24.10.2027Next due date:
30.6.2026Medicine name:
NimenrixMedicine for children:
No
Timeline
Today
8.12.2021Application
15.1.2022Publication
15.2.2024Registration
24.10.2027Expires
Marketing license
IS authorization number:
EU/1/12/767/001-007Date:
16.5.2012
Foreign authorization number:
EU/1/12/767Date:
20.4.2012
Owner
Name:
Pfizer Ireland PharmaceuticalsAddress:
Operations Support Group, Ringaskiddy, County Cork IE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3009146
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 20.01.2024
Type: Frestur til að svara höfnun, fyrsti
Deadline until: 01.01.1